Post by Mediamedic

🎯🌍 ASCO China Voice | World's First HOPE-07 Trial Launches to Advance Perioperative Treatment for HER2-Expressing MIBC A major milestone in urothelial cancer research has been reached with the launch of the world's first HOPE-07 trial, evaluating a disitamab vedotin–based combination for patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the perioperative setting. Leading investigators from centers across China—including Professor Peng Zhang, Professor Ping Tan, Professor Qiang Lü, Professor Shi Fu, Professor Qiao Xiong, Professor Hailong Hu, Professor Zheng Liu, and Professor Mengni Zhang—shared their perspectives on the scientific rationale, trial design, and the potential clinical impact of this landmark study. 📖 Read more to explore the vision behind the HOPE-07 trial, expert insights into HER2-targeted perioperative therapy, and how this pioneering Chinese-led study could reshape the future treatment paradigm for patients with HER2-expressing MIBC. #ASCO2026 #HOPE07 #MIBC #BladderCancer #DisitamabVedotin #RC48 #HER2 #ADC #Immunotherapy #PrecisionMedicine #UrologicOncology